We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

By LabMedica International staff writers
Posted on 22 Oct 2024
Print article
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated number of hip and knee arthroplasties is expected to quadruple within the next 10 to 20 years. PJI impacts over 2% of these patients and has become the leading cause of revision arthroplasty. Rapid and accurate diagnosis of PJI is crucial for ensuring that patients receive the most suitable surgical or antimicrobial treatment plan. Now, a state-of-the-art, high-accuracy point-of-care test is being developed to diagnose PJI in under five minutes.

InfectoTest GmbH (Berlin, Germany) is developing InfectoSynovia, a rapid and high-accuracy test designed to identify PJI in less than five minutes. This test employs an innovative electrochemical analysis technique that requires only a minimal sample of synovial fluid. InfectoSynovia aims to significantly decrease the diagnosis time to under five minutes while providing excellent sensitivity and specificity, using a sample as small as 50 microliters (µl) of synovial fluid.

With InfectoTest's unique electrochemical analysis approach, complemented by software that aids in the precise interpretation of results, InfectoSynovia will be capable of detecting low-grade and culture-negative infections. This groundbreaking technology aims to transform the diagnosis of PJI, addressing an escalating global demand as the prevalence of joint replacements increases with aging populations.

"Our InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection,” said Svetlana Karbysheva, MD, PhD., Managing Director of InfectoTest.

Related Links:
InfectoTest GmbH

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.